Goodrx Holdings, INC Form 4 insider transactions

NASDAQ
Spectrum Equity VII, L.P. and affiliated funds converted Class B Common Stock to Class A Common Stock of GoodRx Holdings, Inc. and distributed shares, with some shares subsequently sold.
NASDAQ
Douglas Joseph Hirsch, Chief Mission Officer at GoodRx Holdings, reports the vesting and conversion of restricted stock units and subsequent transactions involving Class A and Class B common stock.
NASDAQ
Trevor Bezdek, Chairman of GoodRx Holdings, reports the vesting and conversion of restricted stock units and Class B common stock into Class A common stock, along with a disposition of shares to cover tax obligations.
NASDAQ
Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, Inc., sold 79,000 shares of Class A Common Stock on August 12, 2024, at a weighted average price of $6.7674.
NASDAQ
Scott Wagner, Interim CEO of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units on August 8, 2024.
NASDAQ
Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the vesting and subsequent disposal of Class A Common Stock to cover tax obligations.
NASDAQ
Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.
NASDAQ
Agnes Rey-Giraud, a director of GoodRx Holdings, acquired 2,464 shares of Class A Common Stock on July 8, 2024.
NASDAQ
Director Kelly J. Kennedy acquired 2,464 shares of GoodRx Holdings, Inc. Class A common stock on July 8, 2024, and holds 30,862 shares.
NASDAQ
Julie Bradley, a director at GoodRx Holdings, reported acquiring 2,464 shares of Class A common stock on July 8, 2024.
NASDAQ
Director Ian T Clark reports acquisition of 25,852 shares of Class A Common Stock and 51,745 Restricted Stock Units.
NASDAQ
Scott Wagner, Interim CEO of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.
NASDAQ
Douglas Joseph Hirsch, Chief Mission Officer of GoodRx Holdings, Inc., transferred shares of Class A Common Stock to two Grantor Retained Annuity Trusts (GRATs) in transactions dated June 7 and June 10, 2024.
NASDAQ
Trevor Bezdek, Chairman of GoodRx Holdings, reports the transfer of Class A Common Stock to Grantor Retained Annuity Trusts (GRATs) and a transfer by his spouse.
NASDAQ
Julie Bradley, a director at GoodRx Holdings, reported acquiring 28,398 shares of Class A Common Stock on June 6, 2024.
NASDAQ
Kelly J. Kennedy, a director of GoodRx Holdings, Inc., reported acquiring 28,398 shares of Class A common stock on June 6, 2024, through restricted stock units.
NASDAQ
Agnes Rey-Giraud, a director of GoodRx Holdings, Inc., acquired 28,398 deferred stock units on June 6, 2024, according to a recent SEC filing.
NASDAQ
Scott Wagner, Interim CEO of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.
NASDAQ
Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the vesting and subsequent disposal of Class A Common Stock to cover tax obligations.
NASDAQ
Karsten Voermann, CFO of GoodRx Holdings, Inc., reports the disposition of shares to cover tax obligations upon vesting of restricted stock units.
NASDAQ
Douglas Joseph Hirsch, Chief Mission Officer at GoodRx Holdings, reported the acquisition and disposal of Class A and Class B common stock on June 1, 2024.
NASDAQ
Trevor Bezdek, Chairman of GoodRx Holdings, reports the vesting and conversion of restricted stock units and Class B common stock into Class A common stock.
NASDAQ
Scott Wagner, Interim CEO of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units on May 8, 2024.
NASDAQ
Chief Accounting Officer of GoodRx Holdings, Romin Nabiey, reports the vesting and subsequent disposal of Class A Common Stock to cover tax obligations.
NASDAQ
Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the vesting and disposal of restricted stock units and shares of Class A common stock.
NASDAQ
Scott Wagner, Interim CEO of GoodRx Holdings, reports acquisition of restricted stock units and stock options.
NASDAQ
Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the acquisition of restricted stock units and stock options.
NASDAQ
Karsten Voermann, CFO of GoodRx Holdings, Inc., reports the acquisition of restricted stock units and stock options, increasing his beneficial ownership in the company.
NASDAQ
Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the vesting and subsequent disposal of Class A Common Stock to cover tax obligations.
NASDAQ
Karsten Voermann, CFO of GoodRx Holdings, Inc., reported the vesting and subsequent disposal of shares related to restricted stock units on March 8, 2024.